Keywords: synosia, completes, proof-of-concept, rufinamide, trial, usa-based, therapeutics
Synosia completes proof-of-concept rufinamide trial
Article | 28 January 2008
USA-based Synosia Therapeutics, a privately-owned drug development company, has completed the first clinical trial of the sodium channel blocker SYN-111 ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
